Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery
Sponsor : Driehaus Capital Management
Deal Size : $65.0 million
Deal Type : Series B Financing
Confo Secures EUR 60M Series B for GPCR-Modulating Therapies
Details : The proceeds will be used to advance wholly-owned programs, including molecules targeting GPR75, which is being evaluated in the early-stage clinical trial studies for obesity.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 25, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery
Sponsor : Driehaus Capital Management
Deal Size : $65.0 million
Deal Type : Series B Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Flanders Innovation & Entrepreneurship
Deal Size : $1.7 million
Deal Type : Funding
Confo Secures VLAIO Grant for Drug Discovery in Endocrine and Metabolic Diseases
Details : The net proceeds will be used to expand Confo’s ongoing R&D efforts in the discovery of next-generation medicines targeting Class B GPCRs using its patent-protected technology platform.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Flanders Innovation & Entrepreneurship
Deal Size : $1.7 million
Deal Type : Funding
Lead Product(s) : GPCR Antibody
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : AbCellera
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets, leveraging confo's proprietary ConfoBody® technology to stabilize the selected GPCRs in their disease-relevant conformations.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 15, 2023
Lead Product(s) : GPCR Antibody
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : AbCellera
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Confo will lead the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Daiichi Sankyo
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Lilly will continue the clinical development program beyond Phase 1 of CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R) for the treatment of neuropathic pain.
Brand Name : CFTX-1554
Molecule Type : Small molecule
Upfront Cash : $40.0 million
March 02, 2023
Details : CFTX-1554 is a novel inhibitor of AT2R, a clinically precedented target for the treatment of neuropathic pain. CFTX-1554 interacts more efficiently with the AT2R binding site, resulting in improved properties.
Brand Name : CFTX-1554
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2022
Details : The grant will enable to further extend its current universal ConfoBody®, Cb35, toward other G proteins. The funds will also be used to identify additional universal ConfoBodies® for use in ConfoSensor® screening technology and lead neuropathic pain p...
Brand Name : CFTX-1554
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 28, 2022
Details : CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R), is being developed as a non-opioid approach to the treatment of neuropathic pain, while avoiding centrally mediated side effects, such as addiction and sedation.
Brand Name : CFTX-1554
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2022
Lead Product(s) : CFTX-1554
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Confo Therapeutics Expands Patent Estate for ConfoBody®-Based GPCR Screening Platform
Details : The newly added patent cover Confo’s well-established small molecule screening capabilities, which led to the discovery of CFTX-1554 designed to address peripheral neuropathic pain while avoiding centrally mediated side effects, such as addiction and s...
Brand Name : CFTX-1554
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2021
Lead Product(s) : CFTX-1554
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Antibody Medicines
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Confo Therapeutics Enters Collaborative Agreement with Regeneron
Details : The agreement will leverage Confo’s expertise in addressing two GPCR targets for which functional antibodies are needed. Confo’s ConfoBody-based technology platform aims to overcome the limitations of drug discovery on GPCRs.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 30, 2021
Lead Product(s) : Antibody Medicines
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
